Abbott Laboratories (NYSE:ABT) Issues FY 2026 Earnings Guidance

Abbott Laboratories (NYSE:ABT) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 5.380-5.580 for the period, compared to the consensus EPS estimate of 5.550. The company issued revenue guidance of -. Abbott Laboratories also updated its Q2 2026 guidance to 1.250-1.310 EPS.

Abbott Laboratories Stock Performance

NYSE ABT opened at $101.55 on Thursday. The company has a fifty day moving average price of $108.45 and a 200-day moving average price of $119.18. The firm has a market cap of $176.86 billion, a price-to-earnings ratio of 27.30, a PEG ratio of 1.61 and a beta of 0.79. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. Abbott Laboratories has a 1 year low of $99.05 and a 1 year high of $139.06.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.15. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The company had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s payout ratio is presently 67.74%.

Analysts Set New Price Targets

A number of analysts recently commented on the company. BTIG Research decreased their price target on Abbott Laboratories from $140.00 to $131.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Citigroup reduced their price objective on Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a research note on Wednesday, March 11th. Argus cut their price target on shares of Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Raymond James Financial reduced their price target on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Finally, Weiss Ratings lowered shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $134.58.

Insider Buying and Selling

In other news, EVP Elizabeth C. Cushman sold 263 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $30,397.54. Following the completion of the transaction, the executive vice president owned 38,573 shares in the company, valued at $4,458,267.34. This trade represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the sale, the executive vice president directly owned 146,377 shares in the company, valued at approximately $16,918,253.66. This trade represents a 0.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,055 shares of company stock worth $353,097 in the last quarter. 0.46% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Abbott Laboratories

A number of large investors have recently made changes to their positions in ABT. Wellington Management Group LLP grew its position in shares of Abbott Laboratories by 0.8% in the fourth quarter. Wellington Management Group LLP now owns 23,434,760 shares of the healthcare product maker’s stock valued at $2,936,141,000 after purchasing an additional 188,616 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Abbott Laboratories by 0.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,189,528 shares of the healthcare product maker’s stock worth $1,652,517,000 after purchasing an additional 52,191 shares during the period. Amundi grew its holdings in Abbott Laboratories by 28.3% during the 4th quarter. Amundi now owns 8,185,642 shares of the healthcare product maker’s stock valued at $1,025,578,000 after buying an additional 1,803,975 shares in the last quarter. Raymond James Financial Inc. grew its holdings in Abbott Laboratories by 2.0% during the 3rd quarter. Raymond James Financial Inc. now owns 5,536,178 shares of the healthcare product maker’s stock valued at $741,515,000 after buying an additional 107,843 shares in the last quarter. Finally, California Public Employees Retirement System increased its position in shares of Abbott Laboratories by 29.7% during the fourth quarter. California Public Employees Retirement System now owns 5,206,580 shares of the healthcare product maker’s stock valued at $652,332,000 after buying an additional 1,193,410 shares during the period. 75.18% of the stock is owned by institutional investors.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.